Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 15.20
-0.29 (-1.87%)
May 20, 2026, 11:14 AM HKT
Ascletis Pharma Employees
Ascletis Pharma had 202 employees as of December 31, 2025. The number of employees decreased by 29 or -12.55% compared to the previous year.
Employees
202
Change (1Y)
-29
Growth (1Y)
-12.55%
Revenue / Employee
11.17K HKD
Profits / Employee
-1.98M HKD
Market Cap
16.44B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 202 | -29 | -12.55% |
| Dec 31, 2024 | 231 | 12 | 5.48% |
| Dec 31, 2023 | 219 | -59 | -21.22% |
| Dec 31, 2022 | 278 | 12 | 4.51% |
| Dec 31, 2021 | 266 | 10 | 3.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,165 |
| Keymed Biosciences | 1,625 |
| InnoCare Pharma | 1,176 |
| Everest Medicines | 812 |
| Ascentage Pharma Group International | 605 |
| CARsgen Therapeutics Holdings | 355 |
| Duality Biotherapeutics | 231 |
| HBM Holdings | 210 |
Ascletis Pharma News
- 14 days ago - Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) - PRNewsWire
- 20 days ago - Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions - PRNewsWire
- 23 days ago - Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes - PRNewsWire
- 6 weeks ago - Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development - PRNewsWire
- 2 months ago - Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity - PRNewsWire
- 3 months ago - Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development - PRNewsWire
- 4 months ago - Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes - PRNewsWire
- 4 months ago - Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development - PRNewsWire